PTGX News

This week’s three IPOs raised a combined $263 million. Continuing a streak of outperformance from larger IPOs, contract research organization Medpace led with a 21% gain, while Protagonist Therapeutics was the latest biotech IPO to break issue. Currently in the middle of its annual summer hiatus, the IPO market saw no new filings or launches this week. Since the IPO...read more

Protagonist Therapeutics, which is developing peptide-based oral drugs for inflammatory bowel disease, raised $90 million by offering 7.5 million shares at $12, within the range of $11 to $13. The company had originally planned to raise $70 million by offering 5.84 million shares. Insiders had indicated on buying up to $40 million of the IPO. Protagonist Therapeutics plans to list...read more

Four companies are set to raise a combined $270 million in the week ahead. Most notable deal Medpace, a contract research organization focused on biotechs, is joined by two potential customers: Protagonist Therapeutics and Motif Bio. Thanks to insider support, biotechs are the most active segment of the 2016 IPO market, with 20 offerings year-to-date (36% of total), but their...read more

Protagonist Therapeutics, which is developing peptide-based oral drugs for gastrointestinal diseases, announced terms for its IPO on Monday. The Milpitas, CA-based company plans to raise $70 million by offering 5.8 million shares at a price range of $11 to $13. Insiders intend to purchase $40 million worth of shares in the offering. At the midpoint of the proposed range,...read more